Windmill Hill Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Windmill Hill Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$1.53M	Hold	2,745	–	–	0.82%	11
2021 Q1	$1.3M	Buy	+2,745	New	+$1.34M	0.7%	9

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Windmill Hill Asset Management's REGN Position: Q2 2021 in Review

Windmill Hill Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q2 2021 at 2,745 shares worth $1.53M. The position accounts for 0.82% of the portfolio, ranked #11.

Windmill Hill Asset Management first reported a position in REGN in Q1 2021 and has held it in 2 quarters since. 971 funds tracked by Wall St. Rank hold REGN as of Q2 2021.

Windmill Hill Asset Management held 2,745 shares of Regeneron Pharmaceuticals worth $1.53M as of Q2 2021.
Windmill Hill Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q2 2021.
Regeneron Pharmaceuticals made up 0.82% of Windmill Hill Asset Management's portfolio in Q2 2021, its #11 holding.
Windmill Hill Asset Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and has held it in 2 quarters since.
971 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2021.

Based on Windmill Hill Asset Management's 13F filing for Q2 2021, filed 23 Jul 2021.